GlassScriptPhysician profile
Shelley Singh
NPI 1750702171
$10,846.21
in general payments reported to CMS, 2019-2025
34 companies · $1,599 in 2025
The $1,599 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,892 · 2020: $1,087 · 2021: $1,739 · 2022: $1,768 · 2023: $1,503 · 2024: $1,257 · 2025: $1,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,359.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,812.75 | 2019-2025 | Cimzia, Bimzelx |
| Amgen INC. | $1,807.62 | 2019-2025 | Evenity, Prolia, Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $1,030.83 | 2019-2025 | Orencia |
| Abbvie INC. | $975.20 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $742.23 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $647.60 | 2019-2025 | |
| Radius Health, INC. | $610.48 | 2019-2025 | Tymlos |
| Pfizer INC. | $586.31 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $504.11 | 2022-2025 | Saphnelo |
| Janssen Scientific Affairs, LLC | $448.54 | 2019-2022 | |
| Glaxosmithkline, LLC. | $280.37 | 2022-2025 | Benlysta, Nucala |
| Sobi, INC | $203.54 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $117.45 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $112.55 | 2024 | |
| Lilly USA, LLC | $100.86 | 2021-2024 | Taltz |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $95.41 | 2022-2025 | Zilretta, Iovera, Exparel |
| Mallinckrodt Hospital Products INC. | $94.22 | 2020-2021 | |
| Horizon Therapeutics Plc | $89.62 | 2021-2023 | Krystexxa |
| Depuy Synthes Sales INC. | $85.98 | 2022-2023 | Monovisc |
| Organon LLC | $75.60 | 2021-2025 | |
| Genentech USA, INC. | $60.61 | 2023-2025 | Actemra |
| Alkermes, INC. | $58.62 | 2024-2025 | Aristada, Lybalvi |
| Genzyme Corporation | $57.92 | 2019-2020 | |
| Bioventus LLC | $39.68 | 2022-2024 | Supartz Fx Sodium Hyaluronate |
| Mallinckrodt Enterprises LLC | $29.52 | 2019 | |
| Merck Sharp & Dohme LLC | $27.60 | 2020 | |
| Ani Pharmaceuticals, INC. | $25.50 | 2024 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $24.82 | 2025 | |
| Aurinia Pharma U.S., INC. | $24.28 | 2025 | Lupkynis |
| Zimmer Biomet Holdings, INC. | $19.75 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.79 | 2021 | |
| Pacira Therapeutics, INC. | $14.57 | 2020 | |
| Hikma Pharmaceuticals USA | $14.45 | 2019 | |
| Endo Pharmaceuticals INC. | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelley Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.